6970 related articles for article (PubMed ID: 21658326)
1. Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factor-alpha inhibition: more than a coincidental occurrence?
Saggini A; Saraceno R; Chimenti S
Int J Immunopathol Pharmacol; 2011; 24(2):509-15. PubMed ID: 21658326
[TBL] [Abstract][Full Text] [Related]
2. Localized pemphigus foliaceus induced by topical imiquimod treatment.
Lin R; Ladd DJ; Powell DJ; Way BV
Arch Dermatol; 2004 Jul; 140(7):889-90. PubMed ID: 15262711
[No Abstract] [Full Text] [Related]
3. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas.
Rajan N; Langtry JA
Clin Exp Dermatol; 2006 Jan; 31(1):140-1. PubMed ID: 16309513
[No Abstract] [Full Text] [Related]
4. Psoriasis induced by topical imiquimod.
Wu JK; Siller G; Strutton G
Australas J Dermatol; 2004 Feb; 45(1):47-50. PubMed ID: 14961909
[TBL] [Abstract][Full Text] [Related]
5. Pemphigus-like lesions induced by imiquimod.
Bauza A; Del Pozo LJ; Saus C; Martin A
Clin Exp Dermatol; 2009 Jul; 34(5):e60-2. PubMed ID: 19438577
[TBL] [Abstract][Full Text] [Related]
6. Vasodilatory adverse events associated with topical imiquimod 5 percent cream.
Jacobs AA; Snavely N; Markus J; Rosen T
Dermatol Online J; 2008 Apr; 14(4):4. PubMed ID: 18627726
[TBL] [Abstract][Full Text] [Related]
7. Eruptive epidermoid cysts resulting from treatment with imiquimod.
Marty CL; Randle HW; Walsh JS
Dermatol Surg; 2005 Jul; 31(7 Pt 1):780-2; discussion 782-3. PubMed ID: 16029707
[TBL] [Abstract][Full Text] [Related]
8. Treating protruding infantile hemangiomas with topical imiquimod 5% cream caused severe local reactions and disfiguring scars.
Qiu Y; Ma G; Lin X; Jin Y; Chen H; Hu X
Pediatr Dermatol; 2013; 30(3):342-7. PubMed ID: 23046440
[TBL] [Abstract][Full Text] [Related]
9. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy.
Devos SA; Van Den Bossche N; De Vos M; Naeyaert JM
Dermatology; 2003; 206(4):388-90. PubMed ID: 12771494
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod.
Ueyama A; Yamamoto M; Tsujii K; Furue Y; Imura C; Shichijo M; Yasui K
J Dermatol; 2014 Feb; 41(2):135-43. PubMed ID: 24387343
[TBL] [Abstract][Full Text] [Related]
11. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
12. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
13. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
14. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
16. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
17. Psoriasiform eruption and oral ulcerations as adverse effects of topical 5% imiquimod treatment in children: a report of four cases.
Smith WA; Siegel D; Lyon VB; Holland KE
Pediatr Dermatol; 2013; 30(6):e157-60. PubMed ID: 22612595
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Akkilic-Materna M; Massone C; Komericki P
Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod-induced Psoriatic Erythroderma Treated with Infliximab.
Tsutsumi R; Yoshida Y; Yamamoto O
Acta Derm Venereol; 2017 Feb; 97(2):279-280. PubMed ID: 27349505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
